Dae Gon Ha
Stock Analyst at Stifel
(2.70)
# 1,970
Out of 5,138 analysts
54
Total ratings
38.46%
Success rate
9.47%
Average return
Main Sectors:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $92 → $98 | $92.32 | +6.15% | 5 | Dec 16, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $5.45 | +266.97% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $2.09 | +43.54% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $41.95 | +76.40% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $10.38 | -71.10% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $11.87 | +439.17% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $282.01 | -21.99% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $23.50 | +440.43% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $3.71 | +1,193.80% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $3.99 | +351.13% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $1.06 | +560.38% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $86 → $52 | $10.27 | +406.33% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $106.06 | -76.43% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $14.31 | +11.81% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $20.00 | +1,325.00% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.58 | +1,165.82% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.17 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $20.53 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.17 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.00 | +1,100.00% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $18.80 | +2,506.38% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Dec 16, 2025
Maintains: Buy
Price Target: $92 → $98
Current: $92.32
Upside: +6.15%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $5.45
Upside: +266.97%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $2.09
Upside: +43.54%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $41.95
Upside: +76.40%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $10.38
Upside: -71.10%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $11.87
Upside: +439.17%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $282.01
Upside: -21.99%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $23.50
Upside: +440.43%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $3.71
Upside: +1,193.80%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.99
Upside: +351.13%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $1.06
Upside: +560.38%
Aug 10, 2022
Downgrades: Hold
Price Target: $86 → $52
Current: $10.27
Upside: +406.33%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $106.06
Upside: -76.43%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $14.31
Upside: +11.81%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $20.00
Upside: +1,325.00%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.58
Upside: +1,165.82%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.17
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $20.53
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.17
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $1.00
Upside: +1,100.00%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $18.80
Upside: +2,506.38%